World Net Daily News: The Giant, Gaping hole in Sandy Hook Reporting—what psychiatric medications shooter may have been taking

But where, I’d like to ask my colleagues in the media, is the reporting about the psychiatric medications the perpetrator – who had been under treatment for mental-health problems – may have been taking? After all, Mark and Louise Tambascio, family friends of the shooter and his mother, were interviewed on CBS’ “60 Minutes,” during which Louise Tambascio told correspondent Scott Pelley: “I know he was on medication and everything, but she homeschooled him at home cause he couldn’t deal with the school classes sometimes, so she just homeschooled Adam at home. And that was her life.” And here, Tambascio tells ABC News, “I knew he was on medication, but that’s all I know.”

Madness: These statistics could qualify tantrum-throwing children as mentally ill

In an effort to help parents “take the guesswork out of when to worry” about their children and rush them in for screening and treatment, researchers are ready to tell you that your tantrum-throwing kid is mentally ill. To “characterize the emergence of mental health problems” and “chart the progression from normal to abnormal” behavior, a National Institute of Mental Health sponsored study offers the following pathetically weak statistics.

Paxil Class Action Moves on in Canada as Lawsuits Still Filed in U.S.

GlaxoSmithKline, maker of the selective serotonin reuptake inhibitor Paxil, is mired in a class action lawsuit in Canada that alleges the antidepressant caused birth defects in children whose expectant mothers took the drug without the corporation’s adequate warning of the heightened risks. A British Columbia judge permitted the class action.

Psychiatry Panelists with Ties to Drug Industry Urge Antidepressants for Grief

In what some prominent critics have called a bonanza for the drug companies, the American Psychiatric Association this month voted to drop the old warning against diagnosing depression in the bereaved, opening the way for more of them to be diagnosed with major depression — and thus, treated with antidepressants. The change in the handbook, which could have significant financial implications for the $10 billion U.S. antidepressant market, was developed in large part by people affiliated with the pharmaceutical industry, an examination of financial disclosures shows.